Literature DB >> 12810795

Genetically confirmed clinical Huntington's disease with no observable cell loss.

M Caramins1, G Halliday, E McCusker, R J Trent.   

Abstract

Huntington's disease (HD) results from neurodegeneration of the neostriatum. The mutation on chromosome 4 is an expansion in a triplet repeat (CAG)(n) located within the IT15 gene. Only six patients have been reported with clinical features of HD in association with limited neuropathology. Of these, only one has had the diagnosis confirmed by genetic (DNA) testing. We describe a patient with the clinical phenotype and genetically confirmed HD but unexpected limited neuropathology. The patient was seen because of aggressive behaviour and memory problems of two years duration. The differential diagnosis included HD although there was no family history. DNA testing was positive for the HD mutation. Clinical follow up three months later confirmed classic features of HD. Progression of the disease was rapid with death three years later. Neuropathology revealed a largely intact neostriatum with bilateral ischaemic damage and cell loss in the external globus pallidus. Such pathology alone could explain the clinical features of HD. This is only the second report of genetically confirmed clinically manifest HD with little evidence of HD neuropathology. There are several unusual features which could not have been predicted by the clinical picture, in particular the progressive course of bilateral ischaemic changes restricted to the external globus pallidus. The potential to miss other HD cases at post-mortem examination, and the implications of this for family members, are discussed.

Entities:  

Mesh:

Year:  2003        PMID: 12810795      PMCID: PMC1738566          DOI: 10.1136/jnnp.74.7.968

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  6 in total

Review 1.  Alteration of GABAergic neurotransmission in Huntington's disease.

Authors:  Maurice Garret; Zhuowei Du; Marine Chazalon; Yoon H Cho; Jérôme Baufreton
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

2.  Clinical severity of Huntington's disease does not always correlate with neuropathologic stage.

Authors:  Jagan A Pillai; Lawrence A Hansen; Eliezer Masliah; Jody L Goldstein; Steven D Edland; Jody Corey-Bloom
Journal:  Mov Disord       Date:  2012-06-01       Impact factor: 10.338

Review 3.  What do we know about Late Onset Huntington's Disease?

Authors:  Sai S Chaganti; Elizabeth A McCusker; Clement T Loy
Journal:  J Huntingtons Dis       Date:  2017

4.  Differential Alteration in Expression of Striatal GABAAR Subunits in Mouse Models of Huntington's Disease.

Authors:  Zhuowei Du; Margot Tertrais; Gilles Courtand; Thierry Leste-Lasserre; Laura Cardoit; Frédérique Masmejean; Christophe Halgand; Yoon H Cho; Maurice Garret
Journal:  Front Mol Neurosci       Date:  2017-06-20       Impact factor: 5.639

5.  Synaptic RTP801 contributes to motor-learning dysfunction in Huntington's disease.

Authors:  Núria Martín-Flores; Leticia Pérez-Sisqués; Jordi Creus-Muncunill; Mercè Masana; Sílvia Ginés; Jordi Alberch; Esther Pérez-Navarro; Cristina Malagelada
Journal:  Cell Death Dis       Date:  2020-07-30       Impact factor: 8.469

6.  REST overexpression in mice causes deficits in spontaneous locomotion.

Authors:  Li Lu; Anantha Marisetty; Bin Liu; Mohamed Mostafa Kamal; Joy Gumin; Bethany Veo; YouQing Cai; Dina Hamada Kassem; Connie Weng; Mark E Maynard; Kimberly N Hood; Gregory N Fuller; Zhizhong Z Pan; Matthew D Cykowski; Pramod K Dash; Sadhan Majumder
Journal:  Sci Rep       Date:  2018-08-14       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.